DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7r857d/radiation_injury) has announced the addition of the "Radiation Injury - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Radiation Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Injury and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Atox Bio Inc.
- Cleveland BioLabs, Inc.
- Cumberland Pharmaceuticals, Inc.
- Humanetics Corporation
- PharmaIN Corporation
- RestorGenex Corporation
Drug Profiles
- AB-103
- BIO-300
- C-2E5
- CBLB-613
- HSJ-0017
- Recombinant Protein to Activate FGF-4 for Radiation Injury
- Recombinant Protein to Activate FGF-7 for Radiation Injury
- RES-529
- Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury
- Small Molecules to Activate Vitamin D Receptor for Radiation Injury
For more information visit http://www.researchandmarkets.com/research/7r857d/radiation_injury